Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP516475.RA9x0JbC91M42DYTcuuwY5TxiCMy61aCpymLXMKHJFQeE130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516475.RA9x0JbC91M42DYTcuuwY5TxiCMy61aCpymLXMKHJFQeE130_provenance.
• NP679339.RAwOvoYqqBnodXBeNPLbElE7HziZe0EFak66b2C6RFD1k130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679339.RAwOvoYqqBnodXBeNPLbElE7HziZe0EFak66b2C6RFD1k130_provenance.
• NP854114.RA9QimhbHwyHw2sT1KQJ27nEllmCeqgs1h9OUO2xrvhy8130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP854114.RA9QimhbHwyHw2sT1KQJ27nEllmCeqgs1h9OUO2xrvhy8130_provenance.
• NP545130.RAabm-TIb1oGGUS4u09zEOvVpIv7CVGD-So2ti06YzRMs130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545130.RAabm-TIb1oGGUS4u09zEOvVpIv7CVGD-So2ti06YzRMs130_provenance.
• NP545153.RATNJrRv9hKmTu7gQHBEhgtKWIuxu1rTCDc1ZbIzIEnsA130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545153.RATNJrRv9hKmTu7gQHBEhgtKWIuxu1rTCDc1ZbIzIEnsA130_provenance.
• NP964940.RAXSk7z2TUGV0u6l2u7OhTY69c7ubF0Ob4wFwUkjW7gCw130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP964940.RAXSk7z2TUGV0u6l2u7OhTY69c7ubF0Ob4wFwUkjW7gCw130_provenance.
• assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP754391.RADBWzIgOrpFdu2d8nEoBaSWdKIIOe2tHXzxT4CAohjy4130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754391.RADBWzIgOrpFdu2d8nEoBaSWdKIIOe2tHXzxT4CAohjy4130_provenance.
• NP932317.RAqYsd0vKOF_MIjxEyNHuSC_UHbS_avNHSDzY7ZYtPU9w130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP932317.RAqYsd0vKOF_MIjxEyNHuSC_UHbS_avNHSDzY7ZYtPU9w130_provenance.
• NP754394.RAYPBtqULCDlZKiHBLCc-dEDhGeoCp4CjXZbdrqmA6VjQ130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754394.RAYPBtqULCDlZKiHBLCc-dEDhGeoCp4CjXZbdrqmA6VjQ130_provenance.
• NP289665.RApZCynQrg_UzN8Yt8Mk7qEleV0PIiaP5p9y1gYe-tH6A130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP289665.RApZCynQrg_UzN8Yt8Mk7qEleV0PIiaP5p9y1gYe-tH6A130_provenance.
• NP754393.RAuAoMuecp1f1L1NYY9YAMDlDDMyI4_3KMEJ7rz5jXjPc130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754393.RAuAoMuecp1f1L1NYY9YAMDlDDMyI4_3KMEJ7rz5jXjPc130_provenance.
• NP754395.RAopzEmc7unQ8kTj3Coi7ayjn9W-AaOomrAACyORQsuXw130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754395.RAopzEmc7unQ8kTj3Coi7ayjn9W-AaOomrAACyORQsuXw130_provenance.
• NP289645.RAziWyfeJRdjji0kB3WSH2me4XJo8ql4oHjNYgdSSZi7I130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP289645.RAziWyfeJRdjji0kB3WSH2me4XJo8ql4oHjNYgdSSZi7I130_provenance.
• NP964978.RAJgl7Hv-OrJZdQje01LM8VM_2UYuy8057wnBf6sPzBAY130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP964978.RAJgl7Hv-OrJZdQje01LM8VM_2UYuy8057wnBf6sPzBAY130_provenance.
• NP932292.RAE41RtG4QNrWF-1BPhC7sJuyhWjPHjlhqSe_J-Cb6x1o130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP932292.RAE41RtG4QNrWF-1BPhC7sJuyhWjPHjlhqSe_J-Cb6x1o130_provenance.
• NP754390.RAMpRHZY63YkqkfT5tunFnho5fpk4DKgtF2C5M34BK8KQ130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754390.RAMpRHZY63YkqkfT5tunFnho5fpk4DKgtF2C5M34BK8KQ130_provenance.
• NP754392.RALhJk0X5BPxG7tQx6j4UNXTr1cgC283E-mAEM4R8n1uc130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754392.RALhJk0X5BPxG7tQx6j4UNXTr1cgC283E-mAEM4R8n1uc130_provenance.
• NP754396.RAzOEoEYF18BpN7pjOFF0VNTfqQwVeY1QBhRDRtUFJXQ8130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754396.RAzOEoEYF18BpN7pjOFF0VNTfqQwVeY1QBhRDRtUFJXQ8130_provenance.
• NP754397.RA2Uizi-enoFmuOizNZV9Vrr3OU0GtiuhoWEgB6mSFfeQ130_assertion description "[MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754397.RA2Uizi-enoFmuOizNZV9Vrr3OU0GtiuhoWEgB6mSFfeQ130_provenance.